Galectin Therapeutics Inc
Stock Chart, Company Information, and Scan Results
Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.
Galectin Therapeutics Inc Company Information, Fundamentals, and Technical Indicators
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in drug development to create new therapies for fibrotic disease and cancer. The company's lead product candidate is belapectin (GR-MD-02), a galectin-3 inhibitor, which is in a Phase 2 clinical study in MASH patients with advanced fibrosis and a second Phase 2b clinical trial in MASH patients with compensated cirrhosis and portal hypertension. It has a joint venture co-owned by SBH Sciences, Inc. to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.
Galectin Therapeutics Inc In Our Stock Scanner
As of Jun 24, 2026Join Our Free Email List
Get emails from us about ways to potentially make money in the stock market.